Platelet-derived growth factor receptor, Transforming growth factor beta receptor, Vascular endothelial growth factor receptor, and Epidermal growth factor receptor (Group) (PDGFR/TGFBR/VEGFR/EGFR)

This target entry represents a composite of four distinct receptor families: Platelet-derived growth factor receptor (PDGFR), Transforming growth factor beta receptor (TGFBR), Vascular endothelial growth factor receptor (VEGFR), and Epidermal growth factor receptor (EGFR). These receptors are critical mediators of cellular signaling, governing essential processes such as cell growth, survival, angiogenesis, and the epithelial-mesenchymal transition (EMT) (UniProt P00533, P17948, P09619, P36897). While PDGFR, VEGFR, and EGFR are members of the receptor tyrosine kinase (RTK) family, TGFBR functions as a serine/threonine kinase receptor. Dysregulation of these pathways is a hallmark of many malignancies and progressive fibrotic diseases, such as idiopathic pulmonary fibrosis and various solid tumors (PubMed: 28633859). Therapeutic strategies often utilize multi-kinase inhibitors, such as Nintedanib or Vandetanib, to simultaneously inhibit multiple pathways, thereby overcoming redundant signaling and drug resistance (StatPearls: NBK542279). This grouping is typically used in the context of broad-spectrum kinase inhibition targeting both the tumor microenvironment and the cancer cells themselves.

Other names

Receptor Tyrosine Kinases (RTKs)Growth Factor ReceptorsAngiokinase targetsFibrokinase targets

Inhibition of intracellular kinase domains (tyrosine or serine/threonine) to block ATP binding and prevent downstream signaling cascades such as MAPK/ERK, PI3K/Akt, and Smad pathways.